Targeting multidrug-resistant ovarian cancer through estrogen receptor a dependent ATP depletion caused by hyperactivation of the unfolded protein response

Xiaobin Zheng, Neal Andruska, Michael J. Lambrecht, Sisi He, Amadeo Parissenti, Paul J. Hergenrother, Erik R. Nelson, David J. Shapiro

Research output: Contribution to journalArticle

Abstract

Ovarian cancers often recur and tumors acquire resistance to chemotherapy due to overexpression of the ATP-dependent efflux pump, multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1). Nontoxic small molecule inhibitors targeting MDR1 have remained largely elusive. Instead, in a novel application of our recently described estrogen receptor α (ERα) biomodulator, BHPI, we targeted MDR1's substrate, ATP. BHPI depletes intracellular ATP and nearly blocks MDR1-mediated drug efflux in ovarian cancer cells by inducing toxic hyperactivation of the endoplasmic reticulum stress sensor, the unfolded protein response (UPR). BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by > 1,000 fold. BHPI also restored doxorubicin sensitivity in OVCAR-3 cells and in MDR1 overexpressing breast cancer cells. In an orthotopic OVCAR-3 xenograft model, paclitaxel was ineffective and the paclitaxel-treated group was uniquely prone to form large secondary tumors in adjacent tissue. BHPI alone strongly reduced tumor growth. Notably, tumors were undetectable in mice treated with BHPI plus paclitaxel. Compared to control ovarian tumors, after the combination therapy, levels of the plasma ovarian cancer biomarker CA125 were at least several hundred folds lower; moreover, CA125 levels progressively declined to undetectable. Targeting MDR1 through UPR-dependent ATP depletion represents a promising therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)14741-14753
Number of pages13
JournalOncotarget
Volume9
Issue number19
DOIs
StatePublished - Jan 1 2018

Fingerprint

Unfolded Protein Response
Estrogen Receptors
Ovarian Neoplasms
Paclitaxel
Adenosine Triphosphate
P-Glycoprotein
Neoplasms
Endoplasmic Reticulum Stress
Poisons
Immunologic Factors
Tumor Biomarkers
Heterografts
Doxorubicin
Breast Neoplasms
Drug Therapy
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • ATP depletion
  • ERa biomodulator
  • MDR1/P-glycoprotein/ABCB1
  • OVCAR-3 ovarian cancer
  • Unfolded protein response

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting multidrug-resistant ovarian cancer through estrogen receptor a dependent ATP depletion caused by hyperactivation of the unfolded protein response. / Zheng, Xiaobin; Andruska, Neal; Lambrecht, Michael J.; He, Sisi; Parissenti, Amadeo; Hergenrother, Paul J.; Nelson, Erik R.; Shapiro, David J.

In: Oncotarget, Vol. 9, No. 19, 01.01.2018, p. 14741-14753.

Research output: Contribution to journalArticle

@article{a48efad9c4014d39bffc02d647d94d58,
title = "Targeting multidrug-resistant ovarian cancer through estrogen receptor a dependent ATP depletion caused by hyperactivation of the unfolded protein response",
abstract = "Ovarian cancers often recur and tumors acquire resistance to chemotherapy due to overexpression of the ATP-dependent efflux pump, multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1). Nontoxic small molecule inhibitors targeting MDR1 have remained largely elusive. Instead, in a novel application of our recently described estrogen receptor α (ERα) biomodulator, BHPI, we targeted MDR1's substrate, ATP. BHPI depletes intracellular ATP and nearly blocks MDR1-mediated drug efflux in ovarian cancer cells by inducing toxic hyperactivation of the endoplasmic reticulum stress sensor, the unfolded protein response (UPR). BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by > 1,000 fold. BHPI also restored doxorubicin sensitivity in OVCAR-3 cells and in MDR1 overexpressing breast cancer cells. In an orthotopic OVCAR-3 xenograft model, paclitaxel was ineffective and the paclitaxel-treated group was uniquely prone to form large secondary tumors in adjacent tissue. BHPI alone strongly reduced tumor growth. Notably, tumors were undetectable in mice treated with BHPI plus paclitaxel. Compared to control ovarian tumors, after the combination therapy, levels of the plasma ovarian cancer biomarker CA125 were at least several hundred folds lower; moreover, CA125 levels progressively declined to undetectable. Targeting MDR1 through UPR-dependent ATP depletion represents a promising therapeutic strategy.",
keywords = "ATP depletion, ERa biomodulator, MDR1/P-glycoprotein/ABCB1, OVCAR-3 ovarian cancer, Unfolded protein response",
author = "Xiaobin Zheng and Neal Andruska and Lambrecht, {Michael J.} and Sisi He and Amadeo Parissenti and Hergenrother, {Paul J.} and Nelson, {Erik R.} and Shapiro, {David J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10819",
language = "English (US)",
volume = "9",
pages = "14741--14753",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Targeting multidrug-resistant ovarian cancer through estrogen receptor a dependent ATP depletion caused by hyperactivation of the unfolded protein response

AU - Zheng, Xiaobin

AU - Andruska, Neal

AU - Lambrecht, Michael J.

AU - He, Sisi

AU - Parissenti, Amadeo

AU - Hergenrother, Paul J.

AU - Nelson, Erik R.

AU - Shapiro, David J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ovarian cancers often recur and tumors acquire resistance to chemotherapy due to overexpression of the ATP-dependent efflux pump, multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1). Nontoxic small molecule inhibitors targeting MDR1 have remained largely elusive. Instead, in a novel application of our recently described estrogen receptor α (ERα) biomodulator, BHPI, we targeted MDR1's substrate, ATP. BHPI depletes intracellular ATP and nearly blocks MDR1-mediated drug efflux in ovarian cancer cells by inducing toxic hyperactivation of the endoplasmic reticulum stress sensor, the unfolded protein response (UPR). BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by > 1,000 fold. BHPI also restored doxorubicin sensitivity in OVCAR-3 cells and in MDR1 overexpressing breast cancer cells. In an orthotopic OVCAR-3 xenograft model, paclitaxel was ineffective and the paclitaxel-treated group was uniquely prone to form large secondary tumors in adjacent tissue. BHPI alone strongly reduced tumor growth. Notably, tumors were undetectable in mice treated with BHPI plus paclitaxel. Compared to control ovarian tumors, after the combination therapy, levels of the plasma ovarian cancer biomarker CA125 were at least several hundred folds lower; moreover, CA125 levels progressively declined to undetectable. Targeting MDR1 through UPR-dependent ATP depletion represents a promising therapeutic strategy.

AB - Ovarian cancers often recur and tumors acquire resistance to chemotherapy due to overexpression of the ATP-dependent efflux pump, multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1). Nontoxic small molecule inhibitors targeting MDR1 have remained largely elusive. Instead, in a novel application of our recently described estrogen receptor α (ERα) biomodulator, BHPI, we targeted MDR1's substrate, ATP. BHPI depletes intracellular ATP and nearly blocks MDR1-mediated drug efflux in ovarian cancer cells by inducing toxic hyperactivation of the endoplasmic reticulum stress sensor, the unfolded protein response (UPR). BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by > 1,000 fold. BHPI also restored doxorubicin sensitivity in OVCAR-3 cells and in MDR1 overexpressing breast cancer cells. In an orthotopic OVCAR-3 xenograft model, paclitaxel was ineffective and the paclitaxel-treated group was uniquely prone to form large secondary tumors in adjacent tissue. BHPI alone strongly reduced tumor growth. Notably, tumors were undetectable in mice treated with BHPI plus paclitaxel. Compared to control ovarian tumors, after the combination therapy, levels of the plasma ovarian cancer biomarker CA125 were at least several hundred folds lower; moreover, CA125 levels progressively declined to undetectable. Targeting MDR1 through UPR-dependent ATP depletion represents a promising therapeutic strategy.

KW - ATP depletion

KW - ERa biomodulator

KW - MDR1/P-glycoprotein/ABCB1

KW - OVCAR-3 ovarian cancer

KW - Unfolded protein response

UR - http://www.scopus.com/inward/record.url?scp=84991063018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991063018&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10819

DO - 10.18632/oncotarget.10819

M3 - Article

AN - SCOPUS:84991063018

VL - 9

SP - 14741

EP - 14753

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -